CARDIAC



Cardiac magnetic resonance imaging of myocarditis and pericarditis following COVID-19 vaccination: a multicenter collection of 27 cases

Emanuele Angelo Di Dedda^{1,2} · Andrea Barison³ · Giovanni Donato Aquaro³ · Tevfik F Ismail⁴ · Alina Hua⁴ · Cesare Mantini⁵ · Fabrizio Ricci⁵ · Gianluca Pontone⁶ · Alessandra Volpe^{7,8} · Francesco Secchi^{9,10} · Paolo Di Renzi¹¹ · Luigi Lovato¹² · Fabio Niro¹² · Carlo Liguori¹³ · Chiara De Biase¹⁴ · Lorenzo Monti² · Antonio Cirò¹⁵ · Riccardo Marano^{16,17} · Luigi Natale^{16,17} · Eleonora Moliterno¹⁷ · Antonio Esposito^{18,19} · Davide Vignale^{18,19} · Riccardo Faletti²⁰ · Marco Gatti²⁰ · Michele Porcu²¹ · Luca Saba²¹ · Cristina Chimenti²² · Nicola Galea²³ · Marco Francone^{1,2}

Received: 27 August 2021 / Revised: 11 December 2021 / Accepted: 4 January 2022 / Published online: 1 March 2022 © The Author(s), under exclusive licence to European Society of Radiology 2022

Abstract

Objectives To assess clinical and cardiac magnetic resonance (CMR) imaging features of patients with peri-myocarditis following Coronavirus Disease 2019 (COVID-19) vaccination.

Methods We retrospectively collected a case series of 27 patients who underwent CMR in the clinical suspect of heart inflammation following COVID-19 vaccination, from 16 large tertiary centers. Our patient's cohort was relatively young (36.6 ± 16.8 years), predominately included males (n = 25/27) with few comorbidities and covered a catchment area of approximately 8 million vaccinated patients.

Results CMR revealed typical mid-subepicardial non-ischemic late gadolinium enhancement (LGE) in 23 cases and matched positively with CMR T2 criteria of myocarditis. In 7 cases, typical hallmarks of acute pericarditis were present. Short-term follow-up (median = 20 days) from presentation was uneventful for 25/27 patients and unavailable in two cases.

Conclusions While establishing a causal relationship between peri-myocardial inflammation and vaccine administration can be challenging, our clinical experience suggests that CMR should be performed for diagnosis confirmation and to drive clinical decision-making and follow-up.

Key Points

- Acute onset of dyspnea, palpitations, or acute and persisting chest pain after COVID-19 vaccination should raise the suspicion of possible myocarditis or pericarditis, and patients should seek immediate medical attention and treatment to help recovery and avoid complications.
- In case of elevated troponin levels and/or relevant ECG changes, cardiac magnetic resonance should be considered as the best noninvasive diagnostic option to confirm the diagnosis of myocarditis or pericarditis and to drive clinical decision-making and follow-up.

Keywords Magnetic resonance imaging · COVID-19 · Vaccination · Myocarditis · Pericarditis

	Abbreviations AHA	American Heart Association				
	CDC	Centers for Disease				
		Control and Prevention				
	Cine-SSFP	Cine steady-state free precession				
Position statement on COVID-19 vaccines: The authors are firm	CMR	Cardiac magnetic resonance				
supporters of the COVID-19 vaccination campaign and vaccinated them- selves as well.	CMRI	Cardiac magnetic resonance imaging				
Serves as well.	COVID-19	Coronavirus disease 2019				
Marco Francone	ECG	Electrocardiogram				
marco.francone@hunimed.eu	ECV_cmr	Myocardial extracellular volume				
		fraction estimated by CMR				

Ejection fraction
Follow-up days from presentation
High-sensitivity cardiac troponin I
High-sensitivity cardiac troponin T
Late gadolinium enhancement
LGE left ventricular distribution based on
the "17 segments cardiac segmentation
model" by the American
Heart Association
Left ventricular
Indexed left ventricular
end-diastolic volume
LVEDVI estimated by CMR
Left ventricular ejection fraction
LVEF estimated by CMR
Messenger ribonucleic acid
Normal values
Pericarditis detected by CMR
Region of interest
Severe acute respiratory syndrome corona-
virus 2
T2-weighted short-tau inversion recovery
Vaccine Adverse Event Reporting System

Since the beginning of the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, an unprecedented massive effort has been carried out worldwide to rapidly provide acquired immunity against the development of the coronavirus disease 2019 (COVID-19) [1].

As of December 2021, over 8.2 billion doses of a range of different COVID-19 vaccines have been administered, prioritizing distribution to categories that are at highest risk of complications and/or transmission, such as the elderly and the healthcare workers.

While reported side effects following these vaccines have been mild and short-lasting in the overwhelming majority of cases, some series of rare but more significant complications have been collected in various international registries and databases [2].

Myocardial and/or pericardial inflammation is a rare yet known adverse event that has been described in relation to several vaccines (from influenza to smallpox) and also, in recent reports, following SARS-CoV-2 vaccine administration [3, 4].

In the USA, as of November 10, 2021, the Vaccine Adverse Event Reporting System (VAERS) has received 1793 reports of myocarditis or pericarditis happening after COVID-19 vaccination [2]. Of these, the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) did confirm 1049 reports of myocarditis or pericarditis, particularly among male adolescents and young adults aged below 30 after messenger ribonucleic acid (mRNA) COVID-19 vaccination [2].

The underlying pathogenesis is reasonably considered to be multifactorial and likely dependent on the activation of an uncontrolled autoimmune response to the vaccine triggered by molecular mimicry and cross-reaction mechanisms occurring in genetically susceptible individuals [4].

While establishing a causal relationship between myocardial and/or pericardial inflammation and vaccine administration can be challenging, recognition of such a clinical entity can be relevant, not only for epidemiological purposes but also to define the appropriate clinical management and follow-up.

The diagnostic contribution of cardiac magnetic resonance (CMR) to non-invasively depict COVID-19–associated myocarditis and pericarditis has been already extensively described in the acute/active and chronic setting of the disease [5].

We retrospectively collected data from a series of 23 cases observed by 16 large tertiary centers in the period from March to July 2021, representing patients in which CMR was performed between 1 and 25 days after vaccination in the clinical setting of a suspected cardiac involvement. Four patients were scanned between 32 and 82 days after vaccination, due to clinical relapse of a previously documented acute myocarditis.

Diagnosis of acute myocarditis was established according to the updated Lake-Louise criteria [6].

Detailed clinical and imaging features of our patient cohort, composed of a total of 27 patients, are summarized in Table 1.

Briefly, our patient population was relatively young (average age 36.6 ± 16.8 years), mostly included males (n = 25/27) and with few comorbidities; notably, autoimmune disorders were observed in 3/27 cases. In addition to suspected post-vaccine forms of myocardial injury, all recruiting centers were also asked to collect data for all patients who received a CMR diagnosis of acute peri-myocarditis in the same observational period, for comparative purposes. With this regard, our consortium has observed overall 238 cases of myocarditis, including 27 cases in vaccinated patients and 211 in unvaccinated individuals (n = 14 cases with history of COVID-19 disease ; n = 197 unvaccinated without history of COVID-19 disease); a descriptive summary of patients' risk factors and comorbidities among these different groups is displayed in Table 2.

In vaccinated patients, CMR diagnosis of myocarditis and/ or pericarditis more commonly followed immunization with mRNA vaccines (n = 24/27), after the second jab (n = 15/27), and within 10 days from administration (n = 22/27; average 8 \pm 9 days). Clinical presentations included chest pain (n = 25/27), palpitations (n = 10/27), arthralgias and myalgias (n = 9/27), and dyspnea (n = 7/27). High-sensitivity cardiac troponin T (hs-cTnT) or high-sensitivity cardiac troponin I (hscTnI) levels were systematically elevated in 27/27 cases and associated with a variable spectrum of electrocardiogram

S
þ
ed
nat
stii
7
TEDVI
AE
cm
<u> </u>
VEDVI
VED
Ę.
Æ
Ú,
l by
atec
ĨÏ.
est
VEF
ΓΛ
E:
_cn
VEF
ΓΛ
S.
cas
27
he
oft
ŝ
itur
fe
IRI
S
pu
al a
nicí
cli
of
ary
nn
Sur
e 1
able
Ĥ

Table 1 St	Summary of clinical and CMRI features of the 27 cases.	nd CMRI features	of the 27 ca		VEF_cm	LVEF_cmr: LVEF estimated by CMR; LVEDV1_cmr: LVEDV1 estimated by CMR	by CMR; L ¹	VEDVI_cmr:	LVEDVI estim	ated by CMI	~		
Case No. of Vaccine doses	of Vaccine	Days from injection to presentation	Age	Sex]	BMI	Autoimmunities Fever (> 37.5 °C)	Fever (> 37.5 °C)	Chest pain	Chest pain Palpitations Myalgia	Myalgia	Dyspnea	Troponin (hs-cTnT/ cTnl) level baseline	Troponin lab cutoff value
Case 1	Vaxzevria	19	20	M	24.07	0	0	1	0	0	0	593	cTnT < 14
Case 1 2	(Asu azcilicu) Comirnaty (Pfizer/BioNT-		43	X	25.95	0	0	1	-	1	0	706	пуг cTnT < 14 ng/L
Case 1 3	Comirnaty (Pfizer/BioNT-	8	41	ц	31.22	_	0	1	-	0	-	676	cTnT < 14 ng/L
Case 2 4	Comirnaty (Pfizer/BioNT-	c	44	M	28.4	0	0	1	0	1	1	7400	cTnT < 34.2 ng/L
Case 2 5	Comirnaty (Pfizer/BioNT-	4	26	X	23.7	0	1	1	-	0	0	2500	cTnT < 57 ng/L
Case 2 6	Comirnaty (Pfizer/BioNT-	6	41	Z	27.6	0	1	1	-	0	0	5533	cTnT < 57 ng/L
Case 2 7	cui) Spikevax (Moderna)	6	27	Σ	22.5	0	1	1	0	1	0	119	cTnT < 14 ng/L
Case 1	(Modomo)	1	57	Z	23.63	0	1	1	0	0	0	715	cTnT < 14
o Case 1 9	(Mouerna) Comirnaty (Pfizer/BioNT-	5	12	M	17.2	0	0	1	0	0	0	695	пуь cTnT < 14 ng/L
Case 1 10	ecn) Comirnaty (Pfizer/BioNT-	9	20	X	20.43	0	0	П	0	0	0	1406	cTnT < 14 ng/L
Case 2 11	conirnaty (Pfizer/BioNT-	14	18	X	22.09	0	1	1	0	0	0	427	cTnT < 14 ng/L
Case 1 12	conirnaty (Pfizer/BioNT-	c,	33	X	28.3	0	1	1	0	0	0	27	cTnT < 19,8 ng/L
Case 2	Vaxzevria (ActroZeneco)	7	26	N	41.5	0	0	1	0	0	0	2500	cTnT < 14 na/I
Case 2	Vaxzevria (Actra Zeneca)	9	21	Σ	32	0	1	1	1	0	1	657	cTnT < 14 na/I
Case 1	Spikevax (Moderna)	2	49	X	24.62	1	0	1	0	0	0	524	cTnT < 14 na/I
Case 2 16	Comirnaty (Pfizer/BioNT-	ŝ	57	X	25.6	0	0	1	0	0	1	218	cTnT < 14 ng/L
Case 2 17	Comirnaty (Pfizer/BioNT- ech)	٢	26	X	27.4	0	0	1	-	0	0	382	cTnT < 14 ng/L

 $\underline{\textcircled{O}}$ Springer

							2										
cTnT < 14 ng/L	cTnT < 14 ng/L	cTnT < 14 ng/L	cTnT < 14 ng/L	cTnT < 14 ng/L	cTnT < 14 ng/L	cTnT < 14 مم ^ر ا	ng/L cTnT < 34.2 ng/L	cTnT < 14 no/L	cTnT < 14 ng/L		s At FU	0 0	0	0 0	0	0	0
•	Ŭ		Ū	Ū	0	Ū	Ū	Ū	·		FU day	44 49	13	4 82	9	4	35
1790	516	270	378	639	587	1494	216	4209	562	8	Pericarditis_cmr FU days						
1	0	0	0	0	0	1	0	0	П	33 0.25925926146 0.44657608	T2 mapping I global	48 0 65 0	Not 1	performed 56 (3T) 1 Not 0	performed 53 1	Not 0	performed
1	1	0	0	1	1	0	0	1	1	037 0.33333333 2878 0.48038446	ECV_cmr	26 42		performed 27 (3T) Not	performed 33	Not	erformed
1	0	0	0	-	-	0	0	Н	0	2593 0.37037037 8026 0.492102878	T1 mapping global	1026 1201	Not	performed 1280 (3T) Not	performed 1075	Not	performed
1	1	1	1	1	1	1	0	1	0	0.592592593 0.92592593 0.500711744 0.26688026	LGE pattern	Mid-epicardial Mid-epicardial	Mid-epicardial	Mid-epicardial Mid-epicardial	per Mid-epicardial 1075	Mid-epicardial Not	11 11.2.2
1	1	1	1	1	1	0	1	1	1		LGE segments (AHA)	11, 12, 16] 5, 6, 11, 12,] 13, 14, 15, 16	3, 8, 9, 10	4, 5, 10, 15 4, 5, 6, 10, 1	s.	16 1, 4	
0	0	0	0	0	0	0	0	0	-	6 0.1111111111 7 0.320256308		1 1 5	1 2,	1 1 4 4	1 4	1 1	-
33.8	28.1	26.22	23.67	21.39	24.62	20.76	24	26	26.4	25.96926 4.792807	DVI_cmr				121 (dilated)		
55 M	29 M	51 M	31 M	32 M	19 M	20 M	44 M	66 F	80 M	36.5926 16.8163	LVEF_cmr LVEDVI_cmr LGE	89 73	54	67 90	121	94	Ţ
										4 2		1 47 1 50	1 62	1 69 1 70	1 57	1 60	
5	4	б	7	10	23	4	4	46	20	8.22222222 9.540735874	CMR date	27/06/2021 17/06/2021	21/05/2021	25/07/2021 18/03/2021	05/08/2021	15/06/2021	
mirnaty (Pfizer/BioNT-	uitevax (Moderna)	mirnaty (Pfizer/BioNT-	oui) mirnaty (Pfizer/BioNT-	oui) mirnaty (Pfizer/BioNT-	omirnaty (Pfizer/BioNT-	ocu) jikevax (Modarno)	(Pfizer/BioNT-	ecn) iikevax (Moderna)	omirnaty (Pfizer/BioNT-		ECG baseline anomalies	1	1	1 1	1	0	c
Comirnaty (Pfizer/I	Spikevax	Comirnaty (Pfizer/F	Comirnaty (Pfizer/F	Comirnaty (Pfizer/F	Comirnaty (Pfizer/F	Spikevax	Comirnaty (Pfizer/F	ecn) Spikevax (Mode	Comirnaty (Pfizer/F	eviation	Elevated troponins	1 11	1	1 1	1	1	-
Case 2 18	Case 2 19	Case 2 20	Case 2 21	Case 1 22	Case 1 23	Case 1	24 Case 1 25	Case 2 26	Case 2 27	Mean Standard deviation	Case	Case 1 Case 2	Case 3	Case 4 Case 5	Case 6	Case 7	0

🙆 Springer

Table 1	Table 1 (continued)	(p											
Case 9	1	1	14/07/2021 80	95	0		Pericardial	980	25	51	1		0
Case 10	1	0	07/07/2021 58	93.4	1	9	Mid-epicardial	Not	Not	Not	0	25	0
								performed	performed	performed			
Case 11	1	1	18/06/2021 62	63	1	7	Mid-epicardial	1076	29	54	0	43	0
Case 12	1	1	01/04/2021 54	84	1	3, 4, 13, 16	Mid-epicardial	1110	Not	58	0	30	0
									performed				
Case 13	1	0	16/06/2021 56	89.7	1	2, 3, 4, 5, 8,	Epicardial	1157	35	47	0	Unknown Unknown	Unknown
						9, 10, 11							
Case 14	1	1		83	1	4, 5, 6, 11, 12	Epicardial	961	28	46	0	Unknown Unknown	Unknown
Case 15	1	1	18/05/2021 65	50	0			1045	Not	61	0	70	0
									performed				
Case 16	1	1	21/06/2021 59	95.2	0			1037	25.32	50	1	26	0
Case 17	1	1	30/06/2021 61	81.3	0			987	24.28	48	1	6	0
Case 18	1	1		60.9	1	10, 11, 15, 16	Mid-epicardial	1043	25.61	48	0	14	0
Case 19	1	1		76.8	1	4, 5, 10, 11,	Mid-epicardial	1021	31.13	55	0	25	0
						12, 15, 16, 17	a.						
Case 20	1	1	10/07/2021 61	67	1	5	Mid-epicardial 1022	1022	Not	43	0	20	0
									performed				
Case 21	1	1	25/05/2021 75	79	1	3	Mid-epicardial 1030	1030	Not	38	0	62	0
1	,	,		;					performed				
Case 22	1	1	14/07/2021 61	75	-	8	Mid-epicardial 1075	1075	Not 2	59	0	15	0
Cace 73	-	C	19/07/2021 49	88	-	s	Mid-enicardial 1010	1010	performed Not	54	0	13	_
Cu3C 2.7	-	>		00	۲	'n	min maida nitut	0101	nerformed	t,	>	01	
Case 24	1	1	14/07/2021 62	86	1	10, 11, 15, 16	10, 11, 15, 16 Mid-epicardial	Not	Not	Not	0	18	0
								performed	performed	performed			
Case 25	1	1	14/07/2021 59	89.8	1	4.5	Mid-wall	1020	27	52	1	9	0
Case 26	1	1		73	1	4, 5, 10, 11	Mid-epicardial	1175	38	62	0	14	0
Case 27	1	0	15/06/2021 62	111 (dilated)	1	3	Mid-wall	1060	31	55	0	76	0
Mean	1	0.7777778	60.5185185	78.9	0.851852			1055.55	30.02428571	52.35	0.259259259	n =	0
LL	c		3000030 0	1200000011	1100200			CJ (10112C)	1000000000000	LC110L007 7	2007227100	20 D	
stanuaru devia-	D	617600074.0	10/7//0/./	100006666.71 1	410202.0			coc11000.co	coua/ca++.u /c1+7/1060.a +166/0/cc.c cac11000.ca	/ C 1 + 7 / 0 6 0 0	cono/co++.n	z-82	D
tion													

 $\underline{\textcircled{O}}$ Springer

Table 2 Descriptive table reporting prevalence of cardiovascular risk factors and main comorbidities among consecutive patients with a CMR diagnosis of myocarditis and/or pericarditis, observed in the period March–July 2021. Our cohort is categorized into 3 groups: vaccinated: n = 27 vaccinated patients, COVID-19+ (unvaccinated): n = 14 unvaccinated patients with diagnosis of acute or healed COVID-19 disease (based on clinical presentation and PCR confirmation), and COVID-19– (unvaccinated): n = 197 patients, unvaccinated and without history of COVID-19 disease. Definitions of listed risk factors

and comorbidities: hypertension = systolic blood pressure ≥ 130 mmHg or a diastolic blood pressure ≥ 80 mmHg or current medical treatment for hypertension; diabetes = fasting glucose > 126 mg/dL or current treatment; smoking = current smoker or ex-smoker with suspension less than 5 years before observation; hyperlipidemia = LDL > 130 mg/dL or current treatment; moderate/high physical activity = at least 150 min per week of moderate-intensity aerobic activity or 75 min per week of vigorous aerobic activity, or a combination of both; autoimmunities = history of autoimmune diseases

	Age years, (mean)	Gender (%male)	BMI (kg/ m ²) (mean)	Hypertension (%)	Diabetes (%)	Smoking (%)	Moderate/high physical activity (%)	Hyperlipidemia (%)	Autoimmunities (%)
Vaccinated	36.6	92.6	25.9	22.8	6.2	20.4	35.7	22.6	11.1
COVID-19+ (unvaccinated)	46.2	84.8	26.2	25.5	13	29.7	22.4	44.8	9.8
COVID-19- (unvaccinated)	38.2	82.5	24.3	20	10.1	26.5	33.8	29.1	7.2

(ECG) abnormalities including ST–segment elevation and T–wave inversion (n = 21/27).

CMR revealed typical mid-subepicardial non-ischemic late gadolinium enhancement (LGE) in 23 cases and matched positively with CMR T2 criteria of myocarditis (Fig. 1). In 7 cases, CMR showed typical hallmarks of acute pericarditis (effusion with thickening and/or enhancement of pericardial layers).

Left ventricular (LV) systolic function was mildly reduced in 3/27 cases and normal in the remaining population (average ejection fraction: $60.5 \pm 7.7\%$); indexed LV end-diastolic volume (LVEDVI) was normal in all cases ($79 \pm 13 \text{ mL/m}^2$), except for an 80-year-old male and a 41-year-old male presenting with a mildly dilated LV cavity (111 and 121 mL/m^2 , respectively).

Short-term follow-up from presentation was uneventful for 25/27 patients (median = 20 days; range = 2–82 days) and unavailable in two cases.

We collected a case series from the joint efforts of 16 tertiary referral centers, roughly covering a catchment area of approximately 8 million patients vaccinated with at least one dose in the period from March to July. We could therefore estimate an incidence of approximately 3.4 observed cases of myocarditis per million administered doses. Our incidence is significantly lower as compared to most international registries, in which a range of 8.3–34 cases per million was reported (see Fig. 2) [2, 7–9].




Fig. 1 Acute myocarditis 4 days after Spikevax (Moderna) vaccine administration in a 29-year-old patient (images refer to patient n. 19 from Table 1) presenting with infarct-like symptoms of acute chest pain, with ECG ST-elevation changes and troponin rise. End-systolic and end-diastolic cine-SSFP frames (**a** and **b**) show a non-dilated and functionally preserved left ventricular cavity (EF 61%; LVEDVI: 76.8 mL/m²). Typical CMR hallmarks of an acute myocarditis can be observed in "edema-weighted" T2w-STIR short axis plane (**c**), consisting of the presence of a non-ischemic epicardial stria of high

signal intensity involving the anterior- and infero-lateral mid-basal wall (arrows) and closely matching with LGE findings (d) (mid-ventricular level shown). Acute inflammation was also confirmed at myocardial mapping images showing focally increased native T1 mapping (1090 ms of a ROI on the middle-apical lateral wall; n.v. 950–1000 ms; e) and T2 mapping values (avg. 55 ms; n.v. < 50 ms; f) (AHA segments T2 mapping values shown in g). The patient's clinical course was benign and uneventful at 25 days follow-up




Fig. 2 Estimated incidences of myocarditis after COVID-19 vaccine administration derived from our data and as reported in the following government registries or studies: UK (Spikevax) = reported incidence of myocarditis (34 per million doses) after Spikevax (Moderna) vaccine administration in the UK (government report) [7]; Israel (Comirnaty) = reported incidence of myocarditis (26.7 per million doses) after Comirnaty (Pfizer-BioNTech) vaccine administration in Israel (observational retrospective study based on Ministry of Health database) [8]; Canada = reported incidence of myocarditis (23.1 per

This reflects an intrinsic selection difference of our study, in which diagnosis was established with a non-invasive gold standard technique as CMR instead of using clinical diagnostic criteria, like in the Vaccine Adverse Event Reporting System (VAERS), for the CDC, which is a passive reporting system that relies on individuals to send in reports of their experiences [2].

Our findings need to be cautiously contextualized and commented on, because of their potential implications on the perception of vaccine safety by the general population.

A clear causative relationship cannot be established as we only referred to a post-vaccination temporal criterion; moreover, the background prevalence of myocarditis remains uncertain but is likely to be ~ 22 per 100,000 [10]. Finally, myocarditis and pericarditis are also both recognised complications of SARS-CoV-2 and it is entirely plausible that there are overlapping mechanisms involved in both natural infection and vaccine-mediated autoimmunity [11].

Even though we discussed about suspected cardiac side effects of the vaccine, the benefits of the immunization in preventing severe morbidity and mortality from SARS-CoV-2 infection still outweigh the risks of complications after vaccine administration [12].

Further work is required to establish whether there are any adverse sequelae associated with the cases of acute myocarditis observed in this case series; however, the largely preserved LV function and pattern of late enhancement may portend a good prognosis, although the presence of LGE highlights the need for careful surveillance.

million doses) after COVID-19 vaccine administration in Canada (government report) [9]; UK (Comirnaty) = reported incidence of myocarditis (9 per million doses) after Comirnaty (Pfizer-BioNTech) vaccine administration in the UK (government report) [7]; CDC = reported incidence of myocarditis (8.3 per million doses) after COVID-19 vaccines administration in the USA (CDC report) [2]; current research = estimated incidence (3.4 per million doses) from CMR data reported in the present study

Acute onset of dyspnea, palpitations, or acute and persisting chest pain after vaccination should raise the suspicion of possible myocarditis or pericarditis, and patients should seek immediate medical attention and treatment to help recovery and avoid complications. In case of elevated troponin levels and/or relevant ECG changes, CMR should be considered as the best non-invasive diagnostic option to confirm the diagnosis and to drive clinical decision-making and follow-up.

Funding The authors declare this study received no funding.

Declarations

Guarantor The scientific guarantor of this publication is Prof. Marco Francone, MD, PhD.

IRCCS Humanitas Research Hospital, Department of Biomedical Sciences of Humanitas University

ViaRita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy

E-mail: marco.francone@hunimed.eu; phone: +39 0282243076; fax +39 0282242299

Conflict of interest The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

Statistics and Biometry No complex statistical methods were necessary for this paper.

Informed Consent Written informed consent was obtained from all subjects (patients) in this study.

Ethical Approval Ethical approval was obtained from IRB on 25th May 2021, number 2551.

Methodology

- retrospective
- observational
- multicenter study

References

- Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 323:1239–1242
- Centers for Disease Control and Prevention (2021) Selected adverse events reported after COVID-19 vaccination. Centers for Disease Control and Prevention, USA Available via https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html
- Engler RJ, Nelson MR, Collins LC Jr et al (2015) A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination. PLoS One. 10(3):e0118283
- Montgomery J, Ryan M, Engler R et al (2021) Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military. JAMA Cardiol. https://doi.org/10.1001/ jamacardio.2021.2833

- Catapano F, Marchitelli L, Cundari G et al (2021) Role of advanced imaging in COVID-19 cardiovascular complications. Insights Imaging. 24:12–28
- Ferreira VM, Schulz-Menger J, Holmvang G et al (2018) Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 72: 3158–3176
- Medicines and Healthcare products Regulatory Agency (MHRA, Government of the United Kingdom) (2021) Summary of yellow card reporting updated to include figures up to and including 17 nov. Available via https://www.gov.uk/government/publications/ coronavirus-covid-19-vaccine-adverse-reactions/coronavirusvaccine-summary-of-yellow-card-reporting
- Mevorach D, Anis E, Cedar N et al (2021) Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med. 385:2140–2149
- Public Health Agency of Canada (2021) Canadian COVID-19 vaccination safety report. November 26, 2021. Available via https:// health-infobase.canada.ca/covid-19/vaccine-safety/
- Heymans S, Eriksson U, Lehtonen J, Cooper LT Jr (2016) The quest for new approaches in myocarditis and inflammatory cardiomyopathy. J Am Coll Cardiol. 68:2348–2364
- Galea N, Marchitelli L, Pambianchi G et al (2021) T2-mapping increase is the prevalent imaging biomarker of myocardial involvement in active COVID-19: a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 23(1):68
- Pormohammad A, Zarei M, Ghorbani S et al (2021) Efficacy and safety of COVID-19 vaccines: a systematic review and metaanalysis of randomized clinical trials. Vaccines (Basel) 9:467

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Affiliations

Emanuele Angelo Di Dedda^{1,2} • Andrea Barison³ • Giovanni Donato Aquaro³ • Tevfik F Ismail⁴ • Alina Hua⁴ • Cesare Mantini⁵ • Fabrizio Ricci⁵ • Gianluca Pontone⁶ • Alessandra Volpe^{7,8} • Francesco Secchi^{9,10} • Paolo Di Renzi¹¹ • Luigi Lovato¹² • Fabio Niro¹² • Carlo Liguori¹³ • Chiara De Biase¹⁴ • Lorenzo Monti² • Antonio Cirò¹⁵ • Riccardo Marano^{16,17} • Luigi Natale^{16,17} • Eleonora Moliterno¹⁷ • Antonio Esposito^{18,19} • Davide Vignale^{18,19} • Riccardo Faletti²⁰ • Marco Gatti²⁰ • Michele Porcu²¹ • Luca Saba²¹ • Cristina Chimenti²² • Nicola Galea²³ • Marco Francone^{1,2}

Marco Francone marco.francone@hunimed.eu

- ¹ Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan, Italy
- ² IRCCS Humanitas Research Hospital, via Manzoni 56, 20089 Rozzano, Milan, Italy
- ³ Department of Cardiology and Cardiovascular Medicine, Fondazione Toscana Gabriele Monasterio, Via Giuseppe Moruzzi, 1, 56124 Pisa, Italy
- ⁴ School of Biomedical Engineering and Imaging Sciences, King's College London, St Thomas' Hospital, Westminster Bridge Rd, London SE1 7EH, UK
- ⁵ Department of Neuroscience, Imaging and Clinical Sciences, "G.d'Annunzio" University of Chieti-Pescara, Via dei Vestini, 33, 66100 Chieti, CH, Italy

- ⁶ Department of Cardiovascular Imaging, Centro Cardiologico Monzino IRCCS, Via Carlo Parea, 4, 20138 Milan, MI, Italy
- ⁷ Division of Cardiology, Cardiovascular and Thoracic Department, Città della Salute e della Scienza, Corso Bramante, 88, 10126 Turin, TO, Italy
- ⁸ Cardiology, Department of Medical Sciences, University of Turin, Turin, Italy
- ⁹ Department of Biomedical Sciences for Health, Università Degli Studi Di Milano, Via Mangiagalli 31, 20133, Milan, Italy

- ¹⁰ Unit of Radiology, IRCCS Policlinico San Donato, San Donato Milanese, Italy
- ¹¹ Radiology Division, Ospedale "San Giovanni Calibita" Fatebenefratelli Isola Tiberina, Via di Ponte Quattro capi, 39, 00186 Rome, RM, Italy
- ¹² Cardiovascular Radiology Unit Radiology Department, AOU S. Orsola-Malpighi - IRCCS, Via Giuseppe Massarenti, 9, 40138 Bologna, BO, Italy
- ¹³ U.O.C. Diagnostica per Immagini. Ospedale del Mare ASL NA1Centro, Via Enrico Russo, 80147 Naples, Italy
- ¹⁴ U.O.C. Cardiologia UTIC- Emodinamica, Ospedale del Mare -ASL NA1Centro, Via Enrico Russo, 80147 Naples, Italy
- ¹⁵ U.O.C. di Cardiologia e UTIC, Ospedale di Vimercate ASST-Brianza, Via Santi Cosma e Damiano, 10, 20871 Vimercate, Italy
- ¹⁶ Department of Radiological and Hematological Sciences, Section of Radiology, Università Cattolica del Sacro Cuore, L.go Francesco Vito 1, 00168 Rome, Italy

- ¹⁷ Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, Diagnostic Imaging Area, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, L.go Agostino Gemelli 8, 00168 Rome, Italy
- ¹⁸ Experimental Imaging Center, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132 Milan, Italy
- ¹⁹ School of Medicine, Vita-Salute San Raffaele University, Milan, Italy
- ²⁰ Radiology Unit, Department of Surgical Sciences, University of Turin, Città della Salute e della Scienza dì Torino, C.so Bramante 88, 10126 Turin, TO, Italy
- ²¹ Radiology Unit, Department of Medical Sciences, University of Cagliari, Via Università, 40, 09124 Cagliari, Italy
- ²² Department of Cardiovascular, Respiratory, Nephrologic, Anesthesiologic and Geriatric Sciences, "Sapienza" University of Rome, Viale Regina Elena 324, 00161 Rome, Italy
- ²³ Department of Experimental Medicine, "Sapienza" University of Rome, Viale del Policlinico 155, 00161 Rome, Italy